🧠 Watchlist Wednesday: Copy Legendary Investors' Portfolios in One ClickCOPY FOR FREE

Japan stocks flat in tug of war between rising virus cases, stimulus

Published 2020/12/17, 04:45
Updated 2020/12/17, 04:48
© Reuters.
JP225
-
MS
-
TOPX
-
4568
-
4901
-
6954
-
9984
-
7974
-
6178
-
7181
-

By Stanley White

TOKYO, Dec 17 (Reuters) - Japanese shares were little changed in choppy trade on Thursday as concerns about rising domestic coronavirus cases offset optimism over further U.S. economic stimulus and a pledge of support from the Federal Reserve.

The Nikkei 225 Index .N225 was down 0.04% at 26,746.02 by 0214 GMT. The broader Topix .TOPX rose 0.08% to 1,788.37.

Some traders were slightly cautious because Japan is grappling with a third wave of virus infections, but positive developments in the United States supported sentiment. Democrats and Republicans both sounded hopeful about agreeing on a $900 billion COVID-19 aid bill, and the Fed vowed to keep pouring cash into financial markets until the world's largest economy was on a sound footing. could easily fall on profit-taking after a stellar rally that pushed the Nikkei to a 29-1/2-year high last week, but analysts remain positive about the mid-term outlook.

"Excessive amounts of liquidity provided by central banks have been the backbone of stock markets this year, and this will continue into next year," said Norihiro Fujito, chief investment strategist at Mitsubishi UFJ Morgan Stanley (NYSE:MS) Securities.

The stocks that gained the most among the top 30 core Topix names were Nintendo Co Ltd 7974.T up 4.95%, followed by SoftBank Group Corp 9984.T up 3.39%.

The underperformers among the Topix 30 were Daiichi Sankyo Co Ltd 4568.T down 3.80%, followed by Fanuc Corp 6954.T losing 1.83%.

Japan Post Insurance 7181.T rose 11.79% after media reports that it would buy back $2.9 billion of its own shares from its parent Japan Post Holdings 6178.T , whose shares rose 4.12%. Holdings 4901.T fell 3.77% after a media report that Japan's government concluded it could not measure the effectiveness of the company's Avigan drug as a treatment for COVID-19. were 52 advancers on the Nikkei index against 172 decliners.

The volume of shares traded on the Tokyo Stock Exchange's main board .TOPX was 0.5 billion, compared with the average of 1.35 billion in the past 30 days.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.